Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Burkitt Lymphoma 20Leukemia, Myeloid, Acute 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Lymphoma, Non-Hodgkin 5Lymphoma, Mantle-Cell 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Lymphocytic, Chronic, B-Cell 5Leukemia, Biphenotypic, Acute 5Hodgkin Disease 5Congenital Abnormalities 5Lymphoma, Large-Cell, Anaplastic 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Blast Crisis 4Anemia, Refractory, with Excess of Blasts 4Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Hematologic Neoplasms 3Chromosome 5q Deletion Syndrome 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Recurrence 2Primary Myelofibrosis 2

Interventions

Etoposide 4Vincristine 3Rituximab 3Prednisone 3Doxorubicin 3Cyclophosphamide 3prednylidene 2deltacortene 2Cytarabine 2varlilumab 1merphos 1ixazomib 1carmustine, poliferprosan 20 drug combination 1belantamab mafodotin 1Vorinostat 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Methotrexate 1Melphalan 1Immunoglobulin G 1Hydrocortisone 1Disulfides 1Carmustine 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Plasmablastic Lymphoma × merphos × Clear all
NCT02481310 2022-02-21

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Northwestern University

Phase 1/2 Unknown
38 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡